Porth's Essentials of Pathophysiology, 4e

1077

Structure and Function of the Skeletal System

C h a p t e r 4 2

Rogers A, Eastell R. Review: circulating osteoprotegerin and receptor activator for nuclear factor κ B ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005;90:6323–6331. Rosenberg A. Bones, joints, and soft tissue tumors. In: Kumar V, Abbas AK, Fausto N, et al., eds. Robbins and Cotran Pathologic Basis of Disease . 8th ed. Philadelphia, PA: Elsevier Saunders; 2010:1205–1210. Ross MH, Pawlina W. Histology . 6th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011:218–232. Seeman E, Delmas PD. Bone quality—The material and structural basis of bone strength and fragility. N Engl J Med. 2006;344(21):2250–2261. Vega D, Maalouf NM, Sakhaee K. The role of receptor activator of nuclear factor- κ B (Rank)/Rank ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007;92(12):4514–4521.

Xiong J, O’Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res. 2012;29(3):499–505.

Porth Essentials Resources Explore these additional resources to enhance learning for this chapter: •  NCLEX-Style Questions and Other Resources

on

, http://thePoint.lww.com/PorthEssentials4e

• Study Guide for Essentials of Pathophysiology • Adaptive Learning | Powered by PrepU, http://thepoint.lww.com/ prepu